Table 1 Baseline characteristics of the patientsa
RA (n= 17) | SpA (n= 91) | |||||
|---|---|---|---|---|---|---|
Characteristics | ATIpos (n= 7) | ATIneg (n= 10) | Pvalue | ATIpos (n= 14) | ATIneg (n= 77) | Pvalue |
Age, years | 49 (28 to 65) | 47 (36 to 64) | 0.7 | 47 (36 to 73) | 44 (14 to 76) | 0.2 |
Body mass index, kg/m2 | 25.9 (20.2 to 34.8) | 23.5 (16.4 to 34.6) | 0.5 | 24.8 (17.5 to 32.8) | 26.1 (15.8 to 45.8) | 0.1 |
Disease duration, years | 6.0 (1 to 12) | 10 (2 to 30) | 0.07 | 8.9 (0 to 24) | 5 (0 to 24) | 0.3 |
Infliximab dose, mg/kg | 3.0 (2.8 to 3.7) | 3.6 (2.6 to 5.4) | 0.09 | 4.9 (2.9 to 5.7) | 5.0 (2.8 to 6.7) | 0.4 |
Concomitant treatments | ||||||
MTX, n (%) | 3 (43) | 6 (60) | 0.8 | 0 (0) | 25 (32) | 0.03 |
Prednisone, n (%) | 4 (57) | 8 (80) | 0.6 | 2 (14) | 12 (16) | 0.8 |
ESR, mm/hour | 14 (7 to 58) | 24 (2 to 114) | 0.5 | 8 (2 to 54) | 10 (1 to 89) | 0.6 |
CRP, mg/L | 10 (3 to 81) | 16 (3 to 124) | 0.9 | 3 (1 to 72) | 5 (1 to 74) | 0.9 |